Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $119 from $113 and keeps an Overweight rating on the shares. The FDA approved Icotyde for patients with psoriasis a few months ahead of investor expectations, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $104 from $91 at Clear Street
- Icotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target
- Icotyde label upside surprise for Protagonist, says H.C. Wainwright
- Protagonist announces Johnson & Johnson received approval for ICOTYDE
- Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)